# TCL1A

## Overview
TCL1A (T-cell leukemia/lymphoma 1A) is a gene that encodes the protein TCL1 family AKT coactivator A, which plays a pivotal role in the AKT signaling pathway. This protein functions as a coactivator of the AKT kinase, a serine/threonine-specific protein kinase, enhancing its activity and facilitating the phosphorylation of downstream targets involved in cell survival, proliferation, and metabolism (Teitell2005The). The TCL1A protein is characterized by a symmetrical β-barrel structure and is known for its ability to form homodimers, which are essential for its function in cellular signaling (Künstle2002Identification). TCL1A is expressed during early embryogenesis and in specific tissues, particularly during precursor lymphocyte differentiation, and its dysregulation is associated with various lymphoid malignancies (Teitell2005The). The gene's clinical significance is underscored by its involvement in diseases such as T-cell prolymphocytic leukemia, where it is often overexpressed due to genomic rearrangements, contributing to oncogenesis and poor patient prognosis (Schrader2018Actionable).

## Structure
The TCL1A protein is characterized by a symmetrical β-barrel structure composed of eight antiparallel β-strands, organized into two four-stranded β-meander motifs connected by a long loop (Künstle2002Identification). The primary structure of TCL1A includes specific amino acids crucial for its function, such as Asp16 and Ile74, which are important for binding with the Akt kinase (Künstle2002Identification). These residues are located at the beginning of the first β-strand of each β-meander motif, playing a role in stabilizing the structure through electrostatic and hydrophobic interactions (Künstle2002Identification).

The tertiary structure involves the folding of these β-strands into a closed β-barrel, which is essential for its function as an Akt coactivator (Künstle2002Identification). The quaternary structure of TCL1A includes its ability to form homodimers, which is necessary for enhancing Akt kinase activity (Künstle2002Identification). The βC-sheet serves as the dimerization domain, distinct from the Akt binding site (Künstle2002Identification).

TCL1A's interaction with Akt is mediated through the surface formed by the βA and βE sheets, and this interaction is crucial for its role in cellular signaling pathways (Künstle2002Identification).

## Function
TCL1A (T-cell leukemia/lymphoma 1A) is a gene that encodes a protein involved in the AKT signaling pathway, which is crucial for cell survival, proliferation, and metabolism. In healthy human cells, TCL1A acts as a coactivator of AKT kinase, enhancing its activity by forming stable complexes with AKT at the cytoplasmic membrane. This interaction facilitates the phosphorylation of downstream targets, such as glycogen synthase kinase-3β (GSK3β), which are involved in various cellular processes (Teitell2005The).

TCL1A is expressed during early embryogenesis and in specific fetal and adult tissues, particularly during precursor lymphocyte differentiation. It is present in pre-B cells and is downregulated in mature B cells, indicating its role in early immune cell development (Teitell2005The). The protein is primarily active in the cytoplasm and nucleus, where it influences cell survival and proliferation by modulating AKT signal transduction (Teitell2005The).

Proper expression of TCL1A is essential for normal organismal development and immune function. Dysregulation of TCL1A expression can lead to lymphoid malignancies, highlighting its importance in maintaining cellular homeostasis (Teitell2005The).

## Clinical Significance
TCL1A is implicated in several diseases due to its role in oncogenesis and its interactions with signaling pathways. In chemotherapy-induced cardiotoxicity, particularly in women treated with doxorubicin, a significant decrease in TCL1A expression is associated with low ejection fractions, suggesting increased apoptotic sensitivity in cardiac cells (McCaffrey2013Genomic). TCL1A is also involved in clonal hematopoiesis, where its aberrant activation can drive clonal expansion of hematopoietic stem cells. A common polymorphism in the TCL1A promoter is associated with slower clonal expansion, providing a protective effect against certain driver mutations (Weinstock2021Clonal).

In T-cell prolymphocytic leukemia (T-PLL), TCL1A is frequently overexpressed due to genomic rearrangements, leading to enhanced T-cell receptor signaling and immune evasion. This overexpression is linked to poor patient survival and is considered a potential prognostic marker (Schrader2018Actionable). TCL1A's interaction with ATM gene deficiencies contributes to genomic instability and impaired DNA damage response, further promoting leukemogenesis in T-PLL (Schrader2018Actionable). These findings highlight TCL1A's significant role in various malignancies and its potential as a target for therapeutic intervention.

## Interactions
TCL1A, a member of the TCL1 family, is known for its interactions with the AKT kinase, playing a significant role in enhancing AKT activity. This interaction is facilitated by the binding of TCL1A to the pleckstrin homology (PH) domain of AKT, which may stabilize AKT at the membrane and enhance its phosphorylation and activation. This interaction is crucial for the regulation of cell proliferation and survival, as it potentially increases the phosphorylation of downstream AKT targets (Teitell2005The).

TCL1A also forms oligomeric complexes with AKT, which are necessary for its function as an AKT kinase coactivator. The interaction involves specific amino acid residues, such as D16 and I74, which are critical for binding to AKT and for TCL1A's homodimerization, a process essential for its full activity (Künstle2002Identification).

In addition to AKT, TCL1A interacts with other proteins, including HSP70, which regulates its protein folding and stability. The interaction with HSP70 is crucial, as its inhibition leads to TCL1A degradation (Paduano2018TCell). These interactions highlight TCL1A's role in various signaling pathways, contributing to its involvement in oncogenesis.


## References


[1. (Teitell2005The) Michael A. Teitell. The tcl1 family of oncoproteins: co-activators of transformation. Nature Reviews Cancer, 5(8):640–648, August 2005. URL: http://dx.doi.org/10.1038/nrc1672, doi:10.1038/nrc1672. This article has 92 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/nrc1672)

[2. (Künstle2002Identification) Gerald Künstle, Jarmo Laine, Gaelle Pierron, Shin-ichiro Kagami, Hiroshi Nakajima, Francois Hoh, Christian Roumestand, Marc-Henri Stern, and Masayuki Noguchi. Identification of akt association and oligomerization domains of the akt kinase coactivator tcl1. Molecular and Cellular Biology, 22(5):1513–1525, March 2002. URL: http://dx.doi.org/10.1128/mcb.22.5.1513-1525.2002, doi:10.1128/mcb.22.5.1513-1525.2002. This article has 76 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.22.5.1513-1525.2002)

[3. (Schrader2018Actionable) A. Schrader, G. Crispatzu, S. Oberbeck, P. Mayer, S. Pützer, J. von Jan, E. Vasyutina, K. Warner, N. Weit, N. Pflug, T. Braun, E. I. Andersson, B. Yadav, A. Riabinska, B. Maurer, M. S. Ventura Ferreira, F. Beier, J. Altmüller, M. Lanasa, C. D. Herling, T. Haferlach, S. Stilgenbauer, G. Hopfinger, M. Peifer, T. H. Brümmendorf, P. Nürnberg, K. S. J. Elenitoba-Johnson, S. Zha, M. Hallek, R. Moriggl, H. C. Reinhardt, M.-H. Stern, S. Mustjoki, S. Newrzela, P. Frommolt, and M. Herling. Actionable perturbations of damage responses by tcl1/atm and epigenetic lesions form the basis of t-pll. Nature Communications, February 2018. URL: http://dx.doi.org/10.1038/s41467-017-02688-6, doi:10.1038/s41467-017-02688-6. This article has 74 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-017-02688-6)

4. (Weinstock2021Clonal) Clonal hematopoiesis is driven by aberrant activation of TCL1A. This article has 8 citations.

[5. (McCaffrey2013Genomic) Timothy A. McCaffrey, Constantine Tziros, Jannet Lewis, Richard Katz, Robert Siegel, William Weglicki, Jay Kramer, I. Tong Mak, Ian Toma, Liang Chen, Elizabeth Benas, Alexander Lowitt, Shruti Rao, Linda Witkin, Yi Lian, Yinglei Lai, Zhaoqing Yang, and Sidney W. Fu. Genomic profiling reveals the potential role of tcl1a and mdr1 deficiency in chemotherapy-induced cardiotoxicity. International Journal of Biological Sciences, 9(4):350–360, 2013. URL: http://dx.doi.org/10.7150/ijbs.6058, doi:10.7150/ijbs.6058. This article has 26 citations and is from a peer-reviewed journal.](https://doi.org/10.7150/ijbs.6058)

[6. (Paduano2018TCell) Francesco Paduano, Eugenio Gaudio, Afua A. Mensah, Sandra Pinton, Francesco Bertoni, and Francesco Trapasso. T-cell leukemia/lymphoma 1 (tcl1): an oncogene regulating multiple signaling pathways. Frontiers in Oncology, August 2018. URL: http://dx.doi.org/10.3389/fonc.2018.00317, doi:10.3389/fonc.2018.00317. This article has 27 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2018.00317)